The Latest
-
Photo illustration: Mark Harris
Deep Dive // Trump administrationFDA, after turbulent year, leaves drugmakers guessing on its direction
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it’s ever been.
-
Getty Images
Emerging biotechSidewinder secures $137M to advance ‘precision’ ADCs
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
-
Getty Images
News roundupNovo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure
Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are selected.
-
Permission granted by Sanofi
Sanofi immune drug hopeful posts mixed results in mid-stage tests
Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.
-
Alamy
Under-the-skin Tepezza comparable to infused version in key study, Amgen says
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.
-
Getty Images
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street analysts.
-
Getty Images
News roundup
FDA floats new clinical trial reforms; Takeda punts Denali brain drug
In its budget request, the agency proposed a way to speed up early drug testing and help smaller biotech firms. Elsewhere, two startups raised megarounds.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Gilead on Tuesday announced its third company acquisition since late February, agreeing to pay up to $5 billion to acquire Tubulis, a startup developing antibody-drug conjugates for cancer.
Updated April 7, 2026 -
Courtesy of Hims & Hers
Hims & Hers says limited data stolen in social engineering attack
The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.
-
Photo illustration: Mark Harris
Deep DiveA ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma
A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.
-
Alamy
Trump administrationTrump revives pharma tariffs with 100% charges, but leaves loopholes
"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should be low," according to one analyst.
-
Win McNamee via Getty Images
White House seeks 12% cut to HHS in 2027
The Trump administration is requesting about $111 billion in discretionary funding for the HHS, nearly $16 billion less than its budget in 2026.
-
Scott Olson via Getty Images
Obesity drugsFDA approves Lilly obesity pill, triggering battle with Novo Nordisk
Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.
-
Jacob Bell/BioPharma Dive
Q&ABiogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
-
Getty Images
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.
-
Getty Images
mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts
Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.
-
Jeenah Moon via Getty Images
Pfizer, BioNTech to pause COVID vaccine study due to low enrollment
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.
-
Getty Images
IPO windowBiotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026
The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what’s been observed over a similar timeframe in prior years, according to BioPharma Dive data.
-
Ned Pagliarulo/BioPharma Dive
Brain drug revivalLilly beefs up neuroscience pipeline with $6.3B Centessa buyout
The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.
-
Permission granted by Biogen
Biogen, with $5.6B Apellis buy, builds out immunology offerings
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab.
-
Getty Images
Ambrosia adds a megaround for obesity drugs
The $100 million Series B round will be used to bring the biotech’s oral GLP-1 into early human testing.
Updated April 1, 2026 -
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Kailera Therapeutics’ planned IPO would be the first offering for an obesity drugmaker in 2026. The last two metabolic disease-focused companies to go public were Aardvark Therapeutics and Metsera, the latter of which was acquired by Pfizer.
Updated March 30, 2026 -
Getty Images
Blackstone closes $6.3B fund for life sciences investing
It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.
-
Alamy
Merck strikes deal with antibody discovery startup
In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.
-
Getty Images
Viridian tumbles on positive data for key eye drug prospect
The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to an analyst.
